Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Editas Medicine (EDIT) over the last 6 years, with Dec 2024 value amounting to -$2.88.

  • Editas Medicine's EPS (Weighted Average and Diluted) rose 62.67% to -$0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 6.30%. This contributed to the annual value of -$2.88 for FY2024, which is 42.57% down from last year.
  • As of FY2024, Editas Medicine's EPS (Weighted Average and Diluted) stood at -$2.88, which was down 42.57% from -$2.02 recorded in FY2023.
  • In the past 5 years, Editas Medicine's EPS (Weighted Average and Diluted) ranged from a high of -$1.98 in FY2020 and a low of -$3.21 during FY2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$2.88 (2024), whereas its average is -$2.70.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 43.94% in 2021, then soared by 37.07% in 2023.
  • Over the past 5 years, Editas Medicine's EPS (Weighted Average and Diluted) (Yearly) stood at -$1.98 in 2020, then plummeted by 43.94% to -$2.85 in 2021, then dropped by 12.63% to -$3.21 in 2022, then spiked by 37.07% to -$2.02 in 2023, then tumbled by 42.57% to -$2.88 in 2024.